TURNING BLOOD RED: THE FIGHT FOR LIFE IN COOLEY'S ANEMIA
Description:
This book is the story of an inherited blood disease -- Cooley's anemia or beta thalassemia. Cooley's anemia is a severe and potentially fatal anemia that affects millions of people worldwide. Written by a world-recognized expert on the disease who has contributed greatly to the scientific understanding of the pathophysiology of this human hemoglobin disorder, the book describes the emotional and medical impact of the disease on patients and their families. It also summarizes the research on the disease at the level of the genes, DNA, RNA, and proteins. In addition, it also includes chapters on current therapy and future approaches to the disease, such as gene therapy, stem cell transplantation, and antenatal diagnosis.A multidisciplinary book covering the fields of hematology, pediatrics, medicine, genetics, and molecular biology, the book details how Cooley's anemia serves as a model for understanding other human genetic and acquired diseases such as cancer, neurological disorders, and heart disease. It also provides new insights which may lead to new therapies.
Best prices to buy, sell, or rent ISBN 9789812832474
Frequently Asked Questions about TURNING BLOOD RED: THE FIGHT FOR LIFE IN COOLEY'S ANEMIA
The price for the book starts from $8.99 on Amazon and is available from 7 sellers at the moment.
If you’re interested in selling back the TURNING BLOOD RED: THE FIGHT FOR LIFE IN COOLEY'S ANEMIA book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.
As for the TURNING BLOOD RED: THE FIGHT FOR LIFE IN COOLEY'S ANEMIA book, the best buyback offer comes from and is $ for the book in good condition.
The TURNING BLOOD RED: THE FIGHT FOR LIFE IN COOLEY'S ANEMIA book is in very low demand now as the rank for the book is 5,904,178 at the moment. A rank of 1,000,000 means the last copy sold approximately a month ago.
Not enough insights yet.